PF-AtlasClinical Trials › NCT05895136

A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome .

Human albumin · Phase 2

Registry ID
NCT05895136
Phase
Phase 2
Status
Recruiting
Drug / intervention
Human albumin
Sponsor
European Foundation for Study of Chronic Liver Failure
Start
2024-07-01
Enrollment
90
Locations
9

About this trial

The goal of this clinical trial is to determine primarily whether a combinatorial therapy based on the administration of human albumin and enoxaparin is safe and effective in patients with decompensated cirrhosis discharged from the hospital. The main questions it aims to answer are: * Is this combinatorial therapy safe and tolerable? * Is this combinatorial therapy effective? * does this combinatorial therapy cost more or less than standard medical therapy? Participants will attend to study visits in which several test will be performed to asses disease evolution while they are taking study medication. Researchers will compare experimental group treated with combinatorial therapy plus standard treatment with control group treated with standard treatment to see if there are differences in the responses to the questions raised above.

View NCT05895136 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT05895136 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.